Introduction: Magnetic resonance imaging (MRI) is most sensitive and specific for characterizing venous malformations (VMs). VMs typically demonstrate central enhancement on delayed-contrast imaging. Fluid-fluid levels (FFLs) are uncommon in VMs and common in lymphatic malformations (LMs). Technology has advanced since the initial description of these findings. Rates of detection of these MRI findings in VMs may have changed as MRI technology and techniques have evolved. Methods and methods: A prospectively maintained database from a multidisciplinary vascular anomalies clinic was reviewed to identify patients with final diagnosis of VM or LM. Patients with reviewable contrast-enhanced MRIs were selected, reviewing the oldest MRI studies in the database against the newest MRI studies to identify equal numbers of patients from the temporal extremes. Imaging was reviewed to assess for presence of FFLs. Enhancement was quantified by measuring signal in the same location of the lesion both on pre-and postcontrast sequences Results: Forty patients were identified for analysis. Twenty studies with sufficient archived imaging for review were performed between 1995 and 2006; 20 such studies were performed between 2011 and 2012. The new imaging cohort had higher rates of FFL visualization (p ¼ 0.001). Correlation was found between time to imaging following contrast and degree of enhancement (p < 0.001). Inverse correlation was found between scan date and time to contrast (p ¼ 0.001) and scan date and enhancement (p ¼ 0.021). Conclusion: FFLs should no longer be considered exclusionary for the diagnosis of VMs. Timing following contrast administration should be maximized to increase degree of enhancement to confirm the diagnosis of VMs.
Introduction
Magnetic resonance imaging (MRI) is the most sensitive and specific imaging modality for characterization of venous malformations (VMs) because of its superior capability in defining the full extent of lesions and their relationship to adjacent structures. [1] [2] [3] [4] [5] [6] [7] In addition to diagnostic superiority, MRI can be used to track response to treatment. [1] [2] [3] 8 Historically, the presence of two key MRI findings allows for accurate diagnosis of VMs: (a) phleboliths and (b) central enhancement on delayed-contrast imaging. 3, [9] [10] [11] [12] [13] [14] VMs may uncommonly demonstrate fluid-fluid levels (FFLs); however, this finding is more characteristic of lymphatic malformations (LMs). 1, [3] [4] [5] [6] [7] 11, 15, 16 MR technology has advanced considerably since the first description of these key findings. 1 Such technologies include new sequencing techniques and whole-body coils. Heterogeneity exists in interpretation of MR studies for vascular malformations between interpreters and centers. This study seeks to reexamine the classic imaging findings of VMs to see whether rates of detection have changed as technology and techniques have evolved with the aim of providing guidance for MR interpretation to increase diagnostic accuracy. More specifically, describing a lesion as a VM can affect treatment planning and improve outcomes.
Materials and methods
Data queries were performed of a prospectively maintained database from the multidisciplinary birthmarks and vascular anomalies clinic at a major academic medical center to identify patients with a final diagnosis of VM based on imaging and clinical criteria. In retrospective observational fashion, patients with reviewable contrast-enhanced MRIs were identified and evaluated in blinded fashion by a board-certified radiologist. MRIs were performed at 1.5T or 3T. Patients were selected by identifying the oldest MRI studies in the database against the newest MRI studies to identify equal numbers of patients from the two temporal extremes. Imaging was reviewed to assess for presence of FFLs or phleboliths on any pulse sequence, as well as presence of enhancement on postcontrast. Enhancement was quantified by measuring signal in the same three locations of the lesion both on preand postcontrast sequences, targeting the most avidly enhancing segments. When imaging both with and without fat saturation was performed, fat-saturation images were analyzed. Percentage enhancement was calculated by the following formula: (postcontrast signal -precontrast signal)/precontrast signal. The time elapsed between contrast injection and image acquisition was also recorded. Chi-square analysis was performed to compare rates of visualization of FFLs, phleboliths, and enhancement between the older and newer cohorts. Independent sample t test was performed to compare percentage enhancement between the older and newer cohorts. Pearson coefficient was performed to evaluate the correlation between percentage enhancement, time to contrast, and date of imaging (coded as days elapsed between first study in cohort and the study of interest). All statistics were performed using Statistical Package for the Social Sciences (SPSS, version 22, IBM, Armonk, NY).
Results
Forty patients with VMs and archived images sufficient for review were identified for analysis. Twenty studies were performed between 1995 and 2006 (12-year period); 20 studies were performed between 2011 and 2012 (two-year period). No demographic or lesion differences were noted between groups. Differences in imaging features between the two cohorts are summarized in Tables 1 and 2 . The new imaging cohort had higher rates of FFL visualization (55% vs 5%, p ¼ 0.001). No difference was found in rates of phlebolith visualization (55 vs 50%, p ¼ 0.5). There was a positive correlation found between time to imaging following contrast and degree of enhancement (r ¼ 0.6, p < 0.001). There was an inverse correlation found between time to imaging following contrast and scan date (r ¼ -0.5, p ¼ 0.001), as well as scan date and enhancement (r ¼ -0.4, p ¼ 0.02). No demographic or lesion features were associated with imaging markers.
Discussion
Vascular anomalies are classically divided between neoplasms and malformations, and malformations are divided between low-and high-flow lesions involving arteries, veins, or both. 17 Within the rubric established by Mulliken and Glowacki, VMs are low-flow, nonneoplastic lesions of venous origin. 17 MRI allows superior imaging for delineating VMs from adjacent tissues compared to other modalities and affords specificity approaching 100% when combined with clinical features.
1-7 VMs demonstrate variable T1 signal, although they typically are hypointense to isointense relative to muscle. [3] [4] [5] [6] [7] 11, 12 While T1 appearances may differ, VMs characteristically have venous lakes that cause invariably hyperintense appearance on T2 and short inversion time inversion recovery. 1, [3] [4] [5] [6] [7] [9] [10] [11] [12] FFLs are thought to result from hemorrhage within a lesion or accumulation of proteinaceous fluid. 3, 11 Typically, FFLs have been considered diagnostic of LMs, with early characterization of vascular malformations describing their absence in VMs. 1, [3] [4] [5] 7, 11 In our clinical experience, however, we anecdotally noticed detection of FFLs in VMs grew more common with time ( Figure 1) . The current investigation confirms this trend. We postulate that FFLs in VMs represent gravity-dependent layering of red blood cells, which are poorly mixed because of the slow venous flow. The increased detection rate of FFLs in VMs is likely due to higher spatial resolution and signal-to-noise ratio of newer MRI equipment and sequences. Unlike LMs, VMs are contiguous with normal veins, which is why the intraluminal space of VMs will enhance with intravenous contrast. In comparison, LMs will enhance only in their periphery and septa. [3] [4] [5] 7, 9, [11] [12] [13] [14] However, the literature reports different patterns of enhancement in VMs: homogeneous, heterogeneous, patchy, or centripetal. [3] [4] [5] 7, 9, [11] [12] [13] [14] The low-flow nature of VMs also accounts for the variability in enhancement patterns. Sufficiently delayed imaging is necessary to visualize arrival of the intravenous contrast to the VM. 4, 5, 7, 9, [11] [12] [13] [14] The current study confirms that all VMs enhance, and that the degree of enhancement increases with increased amount of time following contrast injection. Newer, faster MRI sequences have decreased the amount of time required to perform postcontrast imaging, which consequently has resulted in less time for VMs to completely equilibrate their blood pool with the intravenous contrast agent. This observation should be taken into consideration when protocoling the delay time for VM studies.
The presence of phleboliths has been considered diagnostic of VMs. 1, [3] [4] [5] 7, 11, 12, 15, 16 These are believed to be calcified thrombi related to venous stasis. Their presence is associated with symptomatic intravascular coagulopathy, so detection is prognostically important and can affect management in addition to improving diagnostic accuracy. 16 Phleboliths were frequently visualized in lesions in the current study. No difference was noted in phlebolith visualization between the old and new imaging cohorts.
An additional future role for expansion of MR evaluation is the use of whole-body MRI. Particularly feasible and useful in pediatric patients, whole-body MRI can delineate the extent and distribution of disease processes in various regions of the body in a single examination, and it can be utilized to evaluate treatment responses.
The current study has several limitations, most of which result from its retrospective nature. Inconsistent availability of historical imaging studies led to a much larger time frame for the old imaging cohort compared to the new cohort. The patients' diagnosis of VM was based on multidisciplinary consensus, which included both clinical and imaging criteria; therefore our imaging observations are in part circular. The imaging protocols were not standardized, and the differences in findings may have been due to protocol differences rather than technology differences. There were demographic differences between the two cohorts, most notably with respect to patient age, although the distribution of lesions themselves was grossly comparable between cohorts. Further prospective analysis is warranted to better evaluate the findings of this study.
Conclusion
With advanced MRI technology, a key distinguishing feature of LMs from VMs may now be less specific. According to our study, FFLs should no longer be considered exclusionary for the diagnosis of VMs. Visualization of phleboliths maintains specificity for VMs using contemporary techniques. Timing following contrast administration should be maximized to increase degree of enhancement to confirm the diagnosis of VMs. Alternatively, blood pool agents that remain confined to the intravascular space can be utilized.
